Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 8/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180647 | 0.78 | LMNA (0.48) | ALDH1A1SMN1; SMN2HPGDHTTTDP1 | |
| SCHEMBL834422 | 0.77 | ALDH1A1 (0.73) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL3602910 | 0.76 | ALDH1A1 (0.50) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL7682354 | 0.75 | DRD1 (0.50) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL10351595 | 0.75 | L3MBTL1 (0.53) | ALDH1A1SMN1; SMN2HPGDHTTTDP1 | |
| SCHEMBL3218241 | 0.75 | PTPN1 (0.42) | ALDH1A1SMN1; SMN2HPGDHTTTDP1 | |
| SCHEMBL10352255 | 0.75 | ALDH1A1 (0.48) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL10351592 | 0.74 | GAA (0.64) | ALDH1A1SMN1; SMN2HPGDHTTTDP1 | |
| SCHEMBL3923636 | 0.74 | MAPT (0.66) | DRD2SMN1; SMN2TDP1L3MBTL1NPC1 | |
| SCHEMBL31409749 | 0.74 | CYP3A4 (0.47) | ALDH1A1SMN1; SMN2HPGDHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080565-B2 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090023777-A1 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-01-22 | — | — | US | disclosed |
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | HUMPHREY JOHN MICHAEL | 2008-09-11 | — | — | US | disclosed |
| US-7381741-B2 | In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors | PFIZER INC (US) | 2008-06-03 | — | — | US | disclosed |
| US-7368463-B2 | Substituted 4-amino-1-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1753718-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1644356-A1 | SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS | Theravance, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005115976-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-03 | — | — | US | disclosed |
| WO-2005007645-A1 | SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PBK, KCND3, KCND2 | DRD1 546/4885DRD2 265/4885DRD4 561/4885 |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | CHRM5, CHRM3, CHRM1 | DRD1 265/4885DRD2 204/4885DRD4 614/4885 |
| US-20090023777-A1 | Substituted 4-amino-benzylpiperidine compounds | CHRM5, CHRM3, GPR4 | DRD1 297/4885DRD2 207/4885DRD4 399/4885 |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PBK, KCND3, KCND2 | DRD1 546/4885DRD2 265/4885DRD4 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.